IL2 and metastatic neoplasm: As RCC is highly resistant to chemotherapy, and its response to cytokine therapy including high-dose interleukin-2 (IL-2) and/or interferon-alfa is less than 20% [2,3], the outcome for patients with metastatic disease is dismal: The 5-year overall survival rate despite systemic treatment is less than 10% [4].